Could Low Altitude Predict the Use of Erythropoietin-Stimulating Agents in Hemodialysis Patients?

Basit Öğe Kaydı
dc.contributor.authorYasar, Emre
dc.contributor.authorAzak, Alper
dc.contributor.authorGirgin, Sinem
dc.contributor.authorOkyay, Gulay Ulusal
dc.contributor.authorPembegul, Irem
dc.date.accessioned2026-04-04T13:33:23Z
dc.date.available2026-04-04T13:33:23Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractIntroduction Altitude may influence the requirement for erythropoiesis-stimulating agent (ESA) therapy in patients undergoing hemodialysis (HD). This study aimed to compare anemia-related parameters, ESA utilization, and intravenous (IV) iron supplementation among HD patients residing at different altitudes. Methods This retrospective-multicenter study was conducted in three provinces of T & uuml;rkiye, each located at a distinct altitude: Balikesir (139 m; low-altitude-group [LA]), Malatya (964 m; moderate-altitude-group [MA]), and Hakkari (1728 m; high-altitude-group[HA]). Results Two hundred and twenty nine HD patients were included in the study: 99 in the LA group, 77 in the MA group, and 53 in the HA group. The mean age was 59 +/- 13 years. ESA use was observed in 92 (93%) patients in the LA group, 61 (73%) in the MA group, and 43 (81%) in the HA group (p = 0.021). Age (OR: 1.102, 95% CI: 1.035-1.174, p = 0.003), female gender (OR: 6.068, 95% CI: 1.080-34.111, p = 0.041), residing at LA (OR: 12.845, 95% CI: 1.833-90.118, p = 0.010), IV iron use (OR: 21.015, 95% CI: 3.397-130.009, p = 0.001), hematocrit (OR: 0.364, 95% CI: 0.229-0.578, p < 0.001), and ferritin (OR: 1.003, 95% CI: 1.001-1.005, p = 0.007) were identified as independent predictors of ESA use. Conclusion Residing at LA was associated with increased ESA requirements in HD patients, suggesting that altitude may be a relevant factor in anemia management.
dc.identifier.doi10.1111/1744-9987.70075
dc.identifier.endpage897
dc.identifier.issn1744-9979
dc.identifier.issn1744-9987
dc.identifier.issue6
dc.identifier.orcid0000-0001-8271-1831
dc.identifier.orcid0000-0002-4609-1580
dc.identifier.orcid0000-0003-4341-9736
dc.identifier.orcid0000-0001-6228-8829
dc.identifier.pmid40855930
dc.identifier.startpage890
dc.identifier.urihttps://doi.org/10.1111/1744-9987.70075
dc.identifier.urihttps://hdl.handle.net/11616/109121
dc.identifier.volume29
dc.identifier.wosWOS:001558864500001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofTherapeutic Apheresis and Dialysis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectaltitude
dc.subjectanemia
dc.subjecterythropoiesis-stimulating agents
dc.subjecthemodialysis
dc.titleCould Low Altitude Predict the Use of Erythropoietin-Stimulating Agents in Hemodialysis Patients?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu